Examining the Impact of Blood Flow Restricted Aerobic Exercise on PGC-1α mRNA Expression in Young Healthy Males

July 11, 2019 updated by: Brendon Gurd, Queen's University

Examining the Impact of Acute Blood Flow Restricted Aerobic Exercise on PGC-1α mRNA Expression in Young Healthy Males: A Randomized Cross-over Trial

This crossover study investigates the effects of restricting arterial blood flow during cycling exercise on PGC-1α and its upstream signalling pathways. In a randomized order, participants will exercise once for 30 minutes with restricted blood flow and then will exercise once for 30 minutes with no blood flow restriction.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Kingston, Ontario, Canada, K7L3N6
        • Queen's University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • 3 hours of physical activity per week
  • No previous cycling training
  • No concurrent involvement in another training program
  • Body mass index < 30 kg/m2

Exclusion Criteria:

  • Presence of cardiovascular disease
  • Presence of metabolic disease
  • Taking regular oral medication
  • Current smoker

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: CTL - BFR
CTL Exercise then BFR Exercise
Other: BFR Exercise
Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).
Other: CTL Exercise
Participants will exercise on a recumbent bike placed on flat ground (CTL).
Experimental: BFR - CTL
BFR Exercise then CTL Exercise
Other: BFR Exercise
Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).
Other: CTL Exercise
Participants will exercise on a recumbent bike placed on flat ground (CTL).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) messenger ribonucleic acid (mRNA)
Time Frame: 15 minutes before exercise and 3 hours post-exercise for both exercise sessions
Fold-change in PGC-1α mRNA expression
15 minutes before exercise and 3 hours post-exercise for both exercise sessions

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Catecholamine concentrations
Time Frame: 15 minutes before exercise and immediately post-exercise for both exercise sessions
Catecholamine concentrations in venous blood
15 minutes before exercise and immediately post-exercise for both exercise sessions
Total and phosphorylated p38 mitogen-activated protein kinase (MAPK)
Time Frame: 15 minutes before exercise and immediately post-exercise for both exercise sessions
Fold change in p38 MAPK phosphorylation
15 minutes before exercise and immediately post-exercise for both exercise sessions
Total and phosphorylated acetyl coenzyme A carboxylase (ACC)
Time Frame: 15 minutes before exercise and immediately post-exercise for both exercise sessions
Fold change in ACC phosphorylation
15 minutes before exercise and immediately post-exercise for both exercise sessions
Total and phosphorylated protein kinase A (PKA)
Time Frame: 15 minutes before exercise and immediately post-exercise for both exercise sessions
Fold change in PKA phosphorylation
15 minutes before exercise and immediately post-exercise for both exercise sessions
Acetylated p53
Time Frame: 15 minutes before exercise and immediately post-exercise for both exercise sessions
Fold change in acetylated p53
15 minutes before exercise and immediately post-exercise for both exercise sessions
Blood lactate
Time Frame: During both exercise sessions (lactate); 15 minutes before and immediately after both exercise sessions
Average [lactate] between conditions
During both exercise sessions (lactate); 15 minutes before and immediately after both exercise sessions
Heart rate (HR)
Time Frame: During both exercise sessions
Average HR between conditions
During both exercise sessions
Revolutions per minute (RPM)
Time Frame: During both exercise sessions
Average RPM between conditions
During both exercise sessions
Ratings of perceived exertion (RPE)
Time Frame: During both exercise sessions
Average RPE between conditions
During both exercise sessions
Oxygenated and deoxygenated hemoglobin
Time Frame: During both exercise sessions and up to 10 minutes after (for cuff occlusion)
Average oxygenated and deoxygenated hemoglobin as a percentage of same day max values
During both exercise sessions and up to 10 minutes after (for cuff occlusion)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Queen's University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2018

Primary Completion (Actual)

January 28, 2019

Study Completion (Actual)

January 28, 2019

Study Registration Dates

First Submitted

October 19, 2018

First Submitted That Met QC Criteria

October 22, 2018

First Posted (Actual)

October 24, 2018

Study Record Updates

Last Update Posted (Actual)

July 15, 2019

Last Update Submitted That Met QC Criteria

July 11, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • BFRNP
  • 402635 (Other Grant/Funding Number: NSERC)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mitochondrial Biogenesis

Clinical Trials on BFR Exercise

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe